Centessa Pharmaceuticals Reports <a href="https://laohu8.com/S/QTWO">Q2</a> 2025 Results: Net Loss Widens to $50.<a href="https://laohu8.com/S/MMM">3M</a>, Increased R&D Spending Highlights Focus on Orexin Agonist Pipeline
Centessa Pharmaceuticals plc has reported its financial results for the second quarter ending June 30, 2025. The company recorded a net loss of $50.3 million, an increase from the $43.8 million net loss in the same period of 2024. General and Administrative expenses rose to $11.9 million compared to $11.2 million the previous year, while Research and Development expenses increased significantly to $42.7 million from $32.8 million in the second quarter of 2024. Cash, cash equivalents, and investments totaled $404.1 million as of June 30, 2025, with the company projecting that these funds will support operations into mid-2027. Centessa Pharmaceuticals continues to advance its orexin receptor 2 (OX2R) agonist franchise, with key data readouts expected within the year. This includes the ORX750 Phase 2a CRYSTAL-1 study for narcolepsy and idiopathic hypersomnia and the ORX142 Phase 1 trial for select neurological disorders. ORX489 remains in IND-enabling studies for neuropsychiatric disorders.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Centessa Pharmaceuticals plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001847903-25-000133), on August 12, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.